# A Study to Examine the Efficacy and Safety of Posaconazole When Introduced Early in the Treatment of Refractory Fungal Infections (P05090 AM2)

> **NCT00550732** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 40 (actual)

## Conditions studied

- Mycoses

## Interventions

- **DRUG:** Posaconazole

## Key facts

- **NCT ID:** NCT00550732
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00550732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00550732, "A Study to Examine the Efficacy and Safety of Posaconazole When Introduced Early in the Treatment of Refractory Fungal Infections (P05090 AM2)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00550732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*